Evidence map›Paper›PMID 18614629›Full record

ArticleJournal of virology2008

Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Emmalene J Bartlett, Ann-Marie Cruz, Janice Esker, Adam Castaño, Henrick Schomacker, Sonja R Surman, Margaret Hennessey, Jim Boonyaratanakornkit, Raymond J Pickles, Peter L Collins and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Exploring lung physiology in health and disease with lung slices.Pulmonary pharmacology & therapeutics · 2011
    Review
  19. Progress in respiratory virus vaccine development.Seminars in respiratory and critical care medicine · 2011
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Emmalene J BartlettLaboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland 20892-8007, USA.
Ann-Marie Cruz
Janice Esker
Adam Castaño
Henrick Schomacker
Sonja R Surman
Margaret Hennessey
Jim Boonyaratanakornkit
Raymond J Pickles
Peter L Collins
Brian R Murphy
Alexander C Schmidt
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USUniversity of North Carolina at Chapel Hill · US

Funding

LABORATORY STUDIES OF PARAINFLUENZA TYPE 3 VIRUSZ01AI000327 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI MURPHY, BRIAN · 1985 to 2008
$2.7M
CFTR Delivery to Ciliated Airway Cells by PIV VectorsR01HL077844 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PICKLES, RAYMOND J · 2005 to 2009
$1.9M
Intramural NIH HHSNHLBI NIH HHS R01 HL077844NHLBI NIH HHS R01 HL77844-1
6 · The paper itself

Abstract

Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to create rHPIV1-P(C-), a virus in which expression of the C proteins (C', C, Y1, and Y2) was silenced without affecting the amino acid sequence of the P protein. Infectious rHPIV1-P(C-) was readily recovered from cDNA, indicating that the four C proteins were not essential for virus replication. Early during infection in vitro, rHPIV1-P(C-) replicated as efficiently as wild-type (wt) HPIV1, but its titer subsequently decreased coincident with the onset of an extensive cytopathic effect not observed with wt rHPIV1. rHPIV1-P(C-) infection, but not wt rHPIV1 infection, induced caspase 3 activation and nuclear fragmentation in LLC-MK2 cells, identifying the HPIV1 C proteins as inhibitors of apoptosis. In contrast to wt rHPIV1, rHPIV1-P(C-) and rHPIV1-C(F170S), a mutant encoding an F170S substitution in C, induced interferon (IFN) and did not inhibit IFN signaling in vitro. However, only rHPIV1-P(C-) induced apoptosis. Thus, the anti-IFN and antiapoptosis activities of HPIV1 were separable: both activities are disabled in rHPIV1-P(C-), whereas only the anti-IFN activity is disabled in rHPIV1-C(F170S). In African green monkeys (AGMs), rHPIV1-P(C-) was considerably more attenuated than rHPIV1-C(F170S), suggesting that disabling the anti-IFN and antiapoptotic activities of HPIV1 had additive effects on attenuation in vivo. Although rHPIV1-P(C-) protected against challenge with wt HPIV1, its highly restricted replication in AGMs and in primary human airway epithelial cell cultures suggests that it might be overattenuated for use as a vaccine. Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and antiapoptosis activities required for virulence in primates.

Indexed as

AnimalsApoptosisBase SequenceCaspase 3Cell LineChlorocebus aethiopsEnzyme ActivationHumansInterferonsMolecular Sequence DataParainfluenza Virus 1, HumanPhosphoproteinsRecombination, GeneticVero CellsViral ProteinsVirus ReplicationCaspase 3C protein, human parainfluenza virus type 1InterferonsPhosphoproteinsP protein, parainfluenza virus 1Viral Proteins

Identifiers

PMID18614629
PMCPMC2546903
OpenAlexW2144705443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.